# Ep11: Stephane Bancel

- **Show:** The Long Run with Luke Timmerman
- **Published:** 31 Jan 2018
- **Source:** https://soundcloud.com/longrunpodcast/ep11-stephane-bancel
- **Transcript:** https://podcasts.opennash.com/shows/the-long-run/ep11-stephane-bancel-36789f/
- **Provider:** OpenNash Podcasts (machine-generated)

## In brief

Stéphane Bancel argues that Moderna's mRNA technology is a true platform. Once the first drug works, later drugs mostly mean changing the sequence of genetic letters. He says this lowers risk and manufacturing cost compared with conventional drugs. He also argues that culture, speed of learning and hard early safety work protect the company better than patents or publicity.

The tension is between an unproven idea and the money and trust it needed. Moderna raised huge sums and said little publicly, which drew comparisons to Theranos. Bancel says he stayed quiet on purpose, so a big drugmaker could not crush the company, and he shows how his Lilly, bioMérieux and Silicon Valley experience shaped his choices, including mistakes like the failed 'ventures' structure.

## Key insights

1. **Manufacturing experience shaped Bancel's career and Moderna** Bancel deliberately took a manufacturing job at Eli Lilly and lived through an FDA-driven halt of biologic launches. That experience got him the bioMérieux CEO job at 32 and shaped how he built Moderna's quality and manufacturing.
2. **Moderna's AstraZeneca deal rested on early safety data** Before any big partner, Moderna ran rat toxicology and tested two drugs in monkeys. It also had the team make 100 proteins in mice, so AstraZeneca could trust the technology was not luck.
3. **Bancel bet on mRNA being a true platform** He says only about a third of human proteins are secreted into blood, where past biotech drugs worked. mRNA could reach the intracellular two-thirds, and later drugs would mainly change the sequence.
4. **Separate venture companies slowed Moderna down** Moderna split into dedicated venture teams after raising money, then merged them back in 2017. Bancel says the key link was between platform discovery and biology discovery, and the split broke it.
5. **Fast learning makes old patents quickly obsolete** Bancel says Moderna still takes patents seriously, but its technology is early on its learning curve. Some patents filed a year or two earlier are already irrelevant. He therefore invests heavily in culture and onboarding, borrowing practices from Google, Facebook and Netflix.

## Questions this episode answers

### What is Moderna actually trying to do with mRNA?

Moderna wants to turn messenger RNA, a molecule that carries instructions for making proteins, into a drug. Host Luke Timmerman says it is injected so cells make the needed protein, and Stéphane Bancel calls the cells 'drug factories'.

### Why did people compare Moderna to Theranos?

Timmerman says the comparison comes from big investment, lofty claims and years of keeping technology details secret, though he says the situations differ. Bancel says Moderna chose not to publish early to protect the company while the science was hard.

### Why did Bancel think an mRNA platform could be cheaper and safer?

He says that once the first drug works, later drugs mostly change the order of letters in the genetic message instead of building a new molecule. He also says the same manufacturing process works for different products.

### How much money did Moderna raise, and what did AstraZeneca pay?

Timmerman says Moderna had about $2 billion in total backing over eight years, including $1.1 billion in equity. He describes the AstraZeneca deal as $240 million up front, and Bancel calls it roughly a quarter billion dollars.

### What mistake did Moderna admit to in how it was organized?

It set up separate 'venture' teams for different disease areas, then merged them back in summer 2017. Bancel says the most important link was between platform scientists and biology scientists, and the split harmed it.

## Facts

- **Luke Timmerman** [0:01:30]: "Moderna has been able to convince enough investors and partners to throw $2 billion behind its efforts over the last eight years to create this new modality of treatment."
- **Stéphane Bancel** [0:05:17]: "We put six new drugs in clinical trial. So today we have 10 drugs in clinical trial, which is a great number"
- **Stéphane Bancel** [0:05:50]: "We had our first phase one for therapeutics that was successful with AstraZeneca for VEGF in the heart, met primary, secondary endpoint."
- **Stéphane Bancel** [0:10:18]: "And so I went from Minnesota straight to Tokyo. And I lived in Tokyo for almost four years."
- **Stéphane Bancel** [0:13:29]: "I graduated in May 2000 which as you know is when the Nasdaq peaked"
- **Stéphane Bancel** [0:18:06]: "because there was a warning letter on the injectable site that was making insulin, all the biologics needed to be injected as well."
- **Stéphane Bancel** [0:19:53]: "we launched new products like Alimta for cancer, Cymbalta for CNS. We launched Cialis which was a really fun product to launch"
- **Stéphane Bancel** [0:20:47]: "of course you are way too young to have a chance I was 32 at the time to have a chance"
- **Stéphane Bancel** [0:24:03]: "We had presence in 42 countries. So we had teams in 42 countries. I think 10 plants around the world, 10 or 11 labs around the world."
- **Stéphane Bancel** [0:28:13]: "showing that they had injected, you know, mRNA-encoded human hippo in a mouse muscle."
- **Stéphane Bancel** [0:30:27]: "around two-thirds of a human protein, a proteome, are intracellular protein. It's only a third that goes into the bloodstream"
- **Stéphane Bancel** [0:36:46]: "we started truly operations and scaling up and hiring people in the summer of 2011."
- **Stéphane Bancel** [0:37:18]: "we tried two drugs in Monkey at the same time because I told myself if we do only one, everybody is going to tell me"
- **Stéphane Bancel** [0:37:56]: "I asked them to do 100 different proteins in mice."
- **Luke Timmerman** [0:35:57]: "AstraZeneca, $240 million up front to develop mRNAs against something like 40 different indications, cardiovascular, metabolic, and a couple of other things."
- **Stéphane Bancel** [0:46:16]: "he set up a breakfast in Gettysburg with Pascal in December of 2012. And so I met Pascal for the first time."
- **Stéphane Bancel** [0:50:36]: "The first round of Moderna, everybody forgets, was $2 million. The A of Moderna was $2 million. The B was $7 million. And the C was $25 million."
- **Stéphane Bancel** [0:54:26]: "after the AZ deal, which happened in March 13, we decided to raise more money"
- **Stéphane Bancel** [0:54:26]: "we went from March 1st of 2013 with literally $20 million in the bank to January 15th JP Morgan 2014 $500 million in the bank"
- **Stéphane Bancel** [0:55:53]: "we explained when we unfolded them last summer, in summer of 17, end of the summer, is we've learned that because the platform is still so raw"
- **Stéphane Bancel** [0:57:21]: "We need to fund the platform, give or take 100 million bucks per year."
- **Stéphane Bancel** [1:02:54]: "from Netflix where the onboarding was two hours where you had Facebook where it was five weeks"
- **Stéphane Bancel** [1:04:36]: "it's a $125 million investment in Norwood in the 10 miles south of Boston it's going"

## Transcript

**[0:00:00] Luke Timmerman:** Welcome to the Long Run. This is a podcast for biotech adventurers. I'm your host, Luke Timmerman. Today's guest is Stefan Bancel. He's the CEO of Cambridge, Massachusetts-based Moderna Therapeutics. The company and the man are somewhat controversial. Google Bancel's name and the people-also-search-for window shows famous entrepreneurs like Jeff Bezos, Elon Musk, and Elizabeth Holmes of Theranos Infamy. Each situation for those entrepreneurs is different, and the comparisons don't hold much water, but a few common themes do stand out.

**[0:00:44] Luke Timmerman:** These are people with big technology ideas, they've attracted big investment, have lofty rhetoric, and a penchant for keeping a lot of crucial technology details secret. They are all lightning rods for critics. Now the idea at Moderna is to turn messenger RNA molecules into drugs themselves. Inject the mRNA code, allow it to get inside cells to produce full functioning proteins, and voila, as Bancel likes to say, drug factories. Dazzling, right? Tantalizing as the concept is, it has long been dismissed as sci-fi.

**[0:01:30] Luke Timmerman:** mRNA, for starters, can't get into cells and make fully functioning proteins without triggering autoimmune reactions to raise one common objection. Yet Moderna has been able to convince enough investors and partners to throw $2 billion behind its efforts over the last eight years to create this new modality of treatment. Most of the money arrived before Moderna had any data in humans. For years, it divulged little about its technology or its preclinical data at scientific conferences. That naturally bred suspicion and, truth be told, some envy.

**[0:02:08] Luke Timmerman:** In this episode, I talk a lot with Bancel about his life, career arc, and influences that shape the way he thinks about Moderna. In the latter part of the show, we talk about some of the particular ups and downs and lessons learned at the company. This episode was recorded at the recent J.P. Morgan Healthcare Conference in San Francisco. And I'll say, Bancel has a French accent, and I occasionally misunderstand a word he says here or there, but I don't think you'll have any trouble listening and understanding what he says.

**[0:02:38] Luke Timmerman:** Before we dive in, a word from the sponsor of the long run, Presage Biosciences. Subscribers to the Timmerman Report newsletter know that I write a lot about cancer R &D. All of the CEOs I talk to are under pressure to get clinical data as soon as humanly possible. Investors demand it, and patients deserve it. Phase 1 clinical trials have traditionally been the very first time that data from patients becomes available. And we all know data from patients is what really matters.

**[0:03:07] Luke Timmerman:** Presage is working to improve this approach. I've covered the company since its early days. They have been working on creating a way for researchers to obtain human data on investigational therapies a year or two before they could with a traditional phase one trial. The business is simple. They're working with biopharma companies to use Presage's patented device that enables intratumoral microdosing of experimental cancer drugs. And here's the thing. It lets researchers assess several drugs at once against a single tumor while the tumor is still in the patient.

**[0:03:43] Luke Timmerman:** The device is being used in a clinical trial right now. To learn more, go to presagebio.com. Lastly, thanks to you for listening. If you work in biotech and like this show, tell your friends. Please leave a comment on iTunes, your favorite podcast app, or on social media. If you like these interviews, you'll also love reading the Timmerman Report. Individuals can subscribe there for $149 a year to get original, analytical, thought-provoking articles that I produce year-round.

**[0:04:16] Luke Timmerman:** Groups that would like to obtain internal sharing rights can also get a group discount. Go to TimmermanReport.com slash subscribe to learn more. Now, join me and Stefan Bancel for the long run. So I'm here at the JPMorgan Healthcare Conference with Stéphane Bancel, the co-founder and CEO of Moderna Therapeutics, a messenger RNA therapeutics developer. Welcome to the long run. Thank you. Thank you for having me. So Stéphane, you and I have been at this conference, I think we've met informally over the years, probably four or five years now.

**[0:04:59] Luke Timmerman:** It's a tradition, I guess. Yes. And this is always an opportunity for companies like yours to kind of lay out some goals for the year, but also reflect a bit on what you accomplished in the past year. So what's your story here at J.P. Morgan in 2018?

**[0:05:17] Stéphane Bancel:** Yeah, so I think the big story for Moderna is the company transformed tremendously in 2017. We put six new drugs in clinical trial. So today we have 10 drugs in clinical trial, which is a great number and represents, I think, amazing work that the team has done. And we have nine additional drugs, so a total of 19, nine additional drugs that are on the way to move to the clinic. And so the big stories are on therapeutics, I think.

**[0:05:50] Stéphane Bancel:** As you know, we built Moderna going one vertical after the other. We started in vaccines back in 2015, our first vertical to move to the clinic. But 2017 was a really big year for therapeutics. We had our first phase one for therapeutics that was successful with AstraZeneca for VEGF in the heart, met primary, secondary endpoint. This is moving to phase two any week now. We had our first oncology therapeutics moving to a clinic. We had our personalized cancer vaccine moving to a clinic.

**[0:06:21] Stéphane Bancel:** And we enabled drugs to be delivered inside the liver, which allowed us to do a lot of genetic disease that aren't drug-able today. And so that's really... Therapeutic is a big word for Moderna in 2017. Okay.

**[0:06:40] Luke Timmerman:** So before we get into some more of the specifics of the Moderna story, you know, you're high profile, you got some controversy, you've had some ups and downs, we'll cover that. But first I wanted to ask just a little bit about you. Sure. where, you know, people may tell the accent, you're from France. Yes. Tell me about where you come from. What did your parents do when you were a kid?

**[0:07:03] Stéphane Bancel:** Yes, so I was born and raised in the south of France in Marseille, so on the sea. So literally the first photo of me after the clinic is on a sailing boat, in a little bassinet, you know, in the cockpit of a sailing boat because my dad is a sailing junkie. and so I grew up you know my mom is a doctor she's retired now my dad was an engineer also retired now they both are cancer survivors and so I just had a great childhood you know super fun to live in the south of France you know you can go sailing anytime you want out to a beach you know windsurfing you get in the car two hours and you're

**[0:07:46] Stéphane Bancel:** in the Alps so like you can ski probably nicely and close to Italy and Spain. So a lot of kind of long weekends in Italy and Spain. So great childhood.

**[0:07:57] Luke Timmerman:** Do you have siblings?

**[0:07:58] Stéphane Bancel:** Yeah, I have a younger brother. He's actually here too this week. He's running a biotech company in Paris. Okay, okay. So it runs in the family. He doesn't. He just happened to be like this.

**[0:08:08] Luke Timmerman:** So how did you get excited about science or the pharmaceutical business?

**[0:08:13] Stéphane Bancel:** So it's interesting because I took a very strange road in the sense I really fell into IT as a kid. I used to code when I was 12, 13 years old. So we should say how old you are here. You're mid-40s, right? Yeah, 45. So that puts your childhood in the 80s. In the 80s, exactly. So I had an Apple IIc as one of my first computers, which was a big deal because it was super expensive.

**[0:08:42] Stéphane Bancel:** And so I already got into, I would say, technology, capital T through the door of IT. And I think because my mom is an MD, I kind of didn't really study biology much in high school. I had a pretty bad grade actually in biology in high school. You were a bit rebellious. Kind of, yes. And so I went to engineering school and I loved chemistry. I just loved chemistry. And so I love biochemistry. And when you do a lot of biochemistry and you do that in the early 90s, you do a lot of genetics.

**[0:09:16] Stéphane Bancel:** And so I went back into biology through genetics, through molecular biology. So on the side, so I was in engineering school in Paris for undergrad. On the side, I took a lot of classes in genetics at the University of Biology and Medicine next to my engineering school in Paris. And then I went, I came to the US to do a Master of Science at Minnesota in biochemical engineering. So basically, I grew antibodies in CHO cells, E.

**[0:09:48] Stéphane Bancel:** coli, yeast systems at the bench. I realized I was not made to do research. It was just the cycle time. The speed clock was not really made for me. And so I just went for a master's and then I went to work. It was too slow. It was too slow. So you got your master's and then what? So then, in the meantime, I had been to Japan for an internship and I fell in love with Japan.

**[0:10:18] Stéphane Bancel:** And so I found a job in Japan. And so I went from Minnesota straight to Tokyo. And I lived in Tokyo for almost four years. So I started for a company, a diagnostic company called Biomare, which later on, I'm sure we'll get to that, I ended up being CEO of. But so I started to work for that company as a sales rep. in Japan, selling medical equipment to food and pharma companies in the QC labs to make sure you don't get bacteria in the food you eat or in the pharmaceutical products.

**[0:10:50] Stéphane Bancel:** Selling in Japan, do you speak Japanese? I used to speak pretty good Japanese, yeah. I know like anything you do in life, you just need a certain set of vocabulary because it's always the same stuff and the same words you use. So I'd work really hard during my undergrad in France, my engineering school. actually spend most of my time not studying engineering but studying genetics and learning

**[0:11:09] Luke Timmerman:** Japanese. So you're not intimidated by these difficult subjects I guess that you know. Yeah

**[0:11:17] Stéphane Bancel:** I'm a believer that if you just work hard at something and you spend the hours you can get pretty good at it you don't have to be great at it you can get pretty good at it and so and so what happened when I was in Japan very quickly because I was generating a lot of sales I was allowed to hire capital reps. So I built a team in Japan. And then, because Japan was doing really good, I was allowed by the head of Asia Pacific to actually start operations in South Korea, in Shanghai in the 90s, in Australia, in Singapore.

**[0:11:53] Stéphane Bancel:** So basically, I ended up still running Japan, but running then the region. Still based in Tokyo. And after a few years doing that, I said, maybe it might be good to get a bit of business education. because he was again still you know this south of france marseille engineer who was doing sales and marketing uh in a fast-growing region because you know in the 90s asia was just you know rocking and so i went to business school where did you do that at harvard i wanted to go to the us because being european i thought it was not a lot of value for me or not the same value if you want to do it in europe and so

**[0:12:28] Stéphane Bancel:** i thought it was it was going to be great to both learn and just be able to just be back in the U.S. again. And so I applied only to U.S. business schools. So you quit BioMario? Yeah, so I quit BioMario. It was a great discussion, nice transition, because it was all planned. So I quit BioMario. I went two months traveling in Asia, for a backpack, and then I went to business school.

**[0:12:51] Luke Timmerman:** So you do that for a couple of years, and what's your goal there at HBS?

**[0:12:57] Stéphane Bancel:** I think, I mean, my goal at school was just learning. I mean I felt super privileged to be in an environment where you know you are super smart people coming from all industries all line of works from you know clinicians to lawyers to bankers to consultants to engineers I mean you're really at everything and so I just feel almost like a kid in a candy store and just you know learning learning learning I'm a very curious guys so it was just fun to be able to do that.

**[0:13:29] Stéphane Bancel:** Sometimes I joke with my wife that I wish I could go back again just for a fun of spending two years and learning stuff and being with smart people. And so what is interesting is I was at HBS. I graduated in May 2000 which as you know is when the Nasdaq peaked and so what was very funny time at the business school is that everybody wanted to be a dot-com entrepreneur of course as they always say in the press you know just look where the HBS grads are going and most probably that's the worst place to invest because it just becomes where everybody goes.

**[0:13:59] Stéphane Bancel:** And so I thought about it a little bit and then I think it's the contrary inside in me and I love healthcare. I really love my years. I love what I've learned in grad school and so on. And so if everybody's going to the tech world and plus I started to build a bit of understanding of a healthcare industry. I said, why don't I stay in healthcare? Nobody's going to healthcare. So it was a very funny time because all the big pharma companies at the time were recruiting on campus, but nobody was going.

**[0:14:32] Stéphane Bancel:** And so I talked to a few companies like Pfizer, Medtronics, and Lilly. And I ended up at Lilly just because I loved the people there. I think I had a better offer at Pfizer. But I just loved the people at Lilly. I loved the products they had. And so I joined the area.

**[0:14:50] Luke Timmerman:** So were you the only member of the HBS class?

**[0:14:52] Stéphane Bancel:** I think we were two. It was two of us. Usually, maybe we recruit 10 or 15 a year. I think that's two of us.

**[0:14:59] Luke Timmerman:** Usually there's investment banking, consulting. Those are popular, as well as dot-com entrepreneurship. But at that time, the Human Genome Project was in the news a lot and coming down the home stretch. But pharma wasn't really using this kind of information.

**[0:15:15] Stéphane Bancel:** And the thing that was interesting is I intuitively initially wanted to go to a small company. And then my uncle, my mom's brother, was my mentor all my career. He made his career in the tech world. He told me, don't go small. He's like, go big. I'm like, why would I go to a big company? It's going to be boring. Bermuda was still at 2 ,000 or 3 ,000 people at the time when I was in Asia working for them.

**[0:15:44] Stéphane Bancel:** he was not started but still small and he said look you have a lot of things to learn you learn a lot of things in big companies you're going to have great bosses you're going to see big problems managing scale and that's something that you're going to use all your career you can always go small you just need to decide to go small and at any stage you can go small and so I only look at the end at big companies which was kind of a bizarre thing for me sometimes Nubar is a co-founder and chairman of Moderna and CEO of Flagship always loved at me is like, I have no idea what you did in big companies for

**[0:16:15] Stéphane Bancel:** 10 years. You must have dreamed them totally crazy, which I did sometimes, yes.

**[0:16:21] Luke Timmerman:** But it's a learning opportunity. This is something I sometimes say to younger people who ask for advice. I think when you're starting out, you want to go someplace where you can learn a lot and not be pigeonholed. So what was your experience there at Eli Lilly?

**[0:16:34] Stéphane Bancel:** I just loved it. Again, company culture was amazing. Very, very people driven. Sometimes I used to joke that Lilly was not in the truck business. they were in the developing people business. And so I worked in the UK, I had a very quick stint in Indianapolis just to get trained after HBS, and I went to the UK because I wanted to go to manufacturing all places. And I wanted to go to manufacturing because as I'd been reading the journal for 10-15 years before business school, I had noticed that every pharma company ended up having manufacturing issues.

**[0:17:12] Stéphane Bancel:** All of them. And it was the most bizarre thing. And I'm like, this must be preventable. So I wanted to go learn. I wanted to learn about the FDA, about CFR, just to learn, you know, the GMP environment. And so I told Lily, I said, I'll come, but I need the manufacturing job. And they looked funny at me at the time because they wanted to give me my marketing job. And I said, but I want to be in the plant.

**[0:17:36] Stéphane Bancel:** I don't want to be in the corporate, just looking at files and folders and so on. I want to really be at the action where it is. And so we sent it to the UK. It was a great experience, had a great team there. And then, true funny story, Lilly had a big issue of FDA when I was in the UK, but in Indianapolis. And so at the time, it was a time where Lilly had a lot of biologics that were ready to launch, great clinical data.

**[0:18:06] Stéphane Bancel:** and because there was a warning letter on the injectable site that was making insulin, all the biologics needed to be injected as well. So they were planned to be coming out of the same plant. And the FDA basically told Lily, until you fix the problem on insulin, because it's a public health matter, because then it's Novo and Lily at the time running most of the supply of the U.S. market, you won't launch any product. No biologic.

**[0:18:32] Stéphane Bancel:** No biologic launch. We have a CEO that has been selling to the street for years. All those cool biologics are coming. FDA said, no, no launching. And so I was...

**[0:18:42] Luke Timmerman:** Manufacturing was important. Fix the brass tacks of how you make insulin first. And then we can talk about this other cool stuff.

**[0:18:50] Stéphane Bancel:** And it was exactly the right thing to do from a public health standpoint. FDA was taking care of a patient as they should. And so I was asked several other people that were posted in plans around the world. basically just move to the US and help. And so I moved to Indianapolis and so it was two years of craziness helping the team deal with manufacturing issues. I had a great boss who went into a small world biotech and pharma, who was brought by Henry Tamir to fix the genzyme issues after the genzyme as you know ran into manufacturing issues too almost 10-15 years later.

**[0:19:27] Stéphane Bancel:** A great great gentleman of the name of Scott Canute. And so I helped the team there and then I told Lily at the time, I said, hey, I'm happy to do one more job in manufacturing, but I really want to go back to the business. And so they said, deal, you come, you help, if everything works well, you go back to the business. And so then I ended up becoming country manager for Belgium. And so I moved to the family from Indy to Brussels.

**[0:19:53] Stéphane Bancel:** And it was a great experience. I was very close to you know, the customers. I was in the field with the reps like a day a week and we launched new products like Alimta for cancer, Cymbalta for CNS. We launched Cialis which was a really fun product to launch because Viagra was of course the only product at the time on the market. We had a lot of pricing issues with the government. Belgium has very low prices.

**[0:20:20] Stéphane Bancel:** We spent a lot of time negotiating prices even like for breast cancer, the indication of genzyme breast cancer was like a year and a half fight just to get it reimbursed, which was crazy. It was the only country in Europe that was not reimbursed. So a lot of learnings there. And at that time, it was one of those funny things that happened in life where Alain Meriot, who was at the time the chairman of Bia Meriot and the founder of Bia Meriot, called me out of the blue one day.

**[0:20:47] Stéphane Bancel:** We just kept in contact, you know, like Christmas letter, you know. And he said, I'm coming to Brussels to see my family I mean can we have lunch? I'm like sure so we have lunch and literally very French we talk about politics and business and what's happening in the world and so on the whole lunch and literally between cheese and dessert you just drop hey we are looking for a new CEO I've been advised to throw a very wide net of course you are way too young to have a chance I was 32 at the time to have a chance

**[0:21:20] Luke Timmerman:** and all you were at this point was sort of the bright young French sales guy who had some success over there in Japan. I mean, it was kind of a strange, it stood out, I'm sure, in his mind. But, you know, I got an HBS degree, did some lily work.

**[0:21:35] Stéphane Bancel:** Yeah. So it's interesting because, so I went for a process. I mean, of course, history, just to look fast, I ended up getting the job. And when I got the job, I asked him, I said, why are you giving me a job? because I'm sure you had much more experience, you know, senior candidates for the job. And he said, you guys have very similar skills on most things like, you know, business, finance, sales and so on.

**[0:21:59] Stéphane Bancel:** The thing that stood out was manufacturing. You are the only candidate that has manufacturing experience and we're making medical devices. By the way, at the time that I joined, I was aware BMRU had a warning letter on the US side. so I had the chance to read the warning letter on the FDA website before saying yes to our job because I wanted to know how bad it was because sometimes it's so bad that it's going to take you five years to dig yourself out of a hole and so it was bad but not too bad and so I took the job and week two in the job I was in a plane to the US to the site because I

**[0:22:35] Stéphane Bancel:** wanted to see for myself and I surprised the team because I went to see the utility room on the roads everywhere and the team was surprised like the new CEO is in the utility room of a plant. What is he doing?

**[0:22:46] Luke Timmerman:** Yeah, I mean, manufacturing. I mean, I'm sure there's a reason why there weren't a lot of candidates with that in their background. It's not a glamorous set of tasks that, you know, I don't think a lot of people raise their hand early in their career to try to, you know, get into the nitty-gritty of this.

**[0:23:02] Stéphane Bancel:** Yeah, and it's funny because, again, at the end of the day, we're all here to make medicines, and, of course, you have to invent the medicine, which is, you know, super hard, it's research, and you have to develop it in the clinic and so on. But to be able to make consistently a high-quality medicine for a long time that you really build the process and the infrastructure and the culture is really important and most organizations don't understand it.

**[0:23:29] Luke Timmerman:** Presage Biosciences has a microinjector device that enables intratumoral microdosing of experimental cancer drugs. Why does this matter? It enables researchers to evaluate several drugs at once against a single tumor while the tumor is still in the patient. It's in clinical trials now. To learn more, go to presagebio.com. Okay, so you go to BioMiru and you're there for a number of years. You're the CEO. It grows a lot. From what to what?

**[0:24:03] Stéphane Bancel:** Oh, I don't remember the numbers now. What I remember is we grew 10 % excluding foreign exchange rates every year for five years. And in terms of global operation? Yeah, so it was a global company. We had presence in 42 countries. So we had teams in 42 countries. I think 10 plants around the world, 10 or 11 labs around the world. So it's really a global company, publicly traded. So it was kind of a big jump.

**[0:24:31] Luke Timmerman:** Yeah, so you're in the deep end of the pool, you start this job at 32, you end up in 37, you're late 30s. How did you make your next step?

**[0:24:43] Stéphane Bancel:** So it's interesting. So when I was at Bumarier, one of the things we did is we did a lot of acquisition of technology company, like early stage, kind of trying to plug the holes to complement our internal R &D. Bumarier was investing a lot in R &D, and that's what I learned from the R &D. I always think about the BMR very similar from a culture standpoint to Roche. She's a family, majority shareholder, several generation long-term view on things, has been in science for several generations before.

**[0:25:15] Stéphane Bancel:** So I've learned kind of a hard way that science takes time and biology is hard. Mr. Meru used to joke, say, yeah, all the projects they ended up taking twice as long and costing twice as much as what we were told at the beginning of a project. It's like, that's just like this biology, Stefan, you just like, can you be used to it? And so, and so what was interesting is...

**[0:25:38] Luke Timmerman:** So this Mr. Miriu, he would have been like the chairman of the board? Yeah, he was the chairman of the board. Working with you as the CEO?

**[0:25:43] Stéphane Bancel:** As the CEO, exactly. And so, you know, we meet regularly, talk about the business and so on. And he was, it was great for me because first he had a lot of experience. He started the company 40 years before. So he saw a company from day one. he had a lot of experience because of different age he had his name on the company name I did not so it was kind of a very great thing to me in terms of coaching and mentoring and it's funny now I went to visit with him just before Christmas because I happened to be Christmas in France this year we flipped with my wife being American when you're in France, when you're in the

**[0:26:18] Stéphane Bancel:** US and I went to see him in Lyon and I told him you have no idea the number of things I've done at Moderna because of what I learned from you, how you built and the culture you had at Bumerio. So anyway, so we did a lot of acquisition at Bumerio, 10, if my memory is correct, so kind of two per year. And technology, so early stage staff to plug the holes where the R &D or to complement what we were doing in R &D.

**[0:26:46] Stéphane Bancel:** And through that process, we must have looked at, I don't know, 40, 60, 70 companies, you know, like you look at a lot of stuff before picking the ones you like. We made our mistakes, obviously. We made one other acquisition. I wish we had not made. So we just cleaned our mess after. But through that process, I got to meet a lot of VCs in the US because two further companies we bought were in the US.

**[0:27:11] Stéphane Bancel:** And so I got to meet a lot of VCs and get to see them regularly. And then the phone call started to rank. Say, hey, Stefan, hey, we have this super cool company. Would you be interested in running it? not just buying it yeah running it so that became an interesting discussion and and it was initially mostly on the diagnostic side and then people realized that through the early years I spent quite a number of years you know pharmaceuticals and so then it started to be on the biotech side where people say hey we have those cool molecules and so on and most of the phone calls were interesting but they were mostly you know kind of a typical biotech

**[0:27:46] Stéphane Bancel:** company you know one or two product I'm not a gambler you know when you look at the probability of taking a success of molecules One or two assets, the chance that you go home with nothing is pretty high. I'm like, oof. So I was always kind of declining politely. And one day, it clearly changed my life. It's the day when Nubar called me. Nubar a fan of flagship ventures. Yeah. So I had known Nubar for a few years.

**[0:28:13] Stéphane Bancel:** We actually had been on the board together, one of the flagship companies. And Nubar called me. and he's like, come and see me. And so I went to see Nobar. It was easy. I was a few blocks away from Nobar. And he showed me the first experiment, which was going to become Moderna, which was an experiment coming from, you know, the Rossi labs at Harvard, showing that they had injected, you know, mRNA-encoded human hippo in a mouse muscle.

**[0:28:43] Stéphane Bancel:** And they had found in the mouse blood human hippo, which you can differentiate because of the amino acid is different from mouse hippos. It was really the human version, not the mouse version. And the red cells of a mouse were going through the roof like if it was a kind of hippo from Amgen. And I remember looking at the data on the table and telling Nubar this is fake, this is not possible. And I told him, we have all been trained in grad school that mRNA would never be a drug.

**[0:29:09] Stéphane Bancel:** It's super unstable, it's immunogenic, it doesn't look like a cool drug. And Nubar was very, very good. And I'm thankful that he was very good because I might have just walked away from what became Moderna is it only looks like you're a big company guy you spend your time saying no because your teams have more ideas than you guys have money to invest it's true of any company in the world but our job here at Flagship is to invent the future we don't like to do things that other people do we like to do things that are really you know super innovative, of course, it's more risky, and we love platforms.

**[0:29:46] Stéphane Bancel:** So I'm not asking you to believe this is true, but just because you're here and out of friendship, nobody totally flipped me like a pancake, or I should say a crab, actually, by saying that, because I let my guard down, and he said, what if this is true? What does he mean if this is true? And very Nuba, kind of very humble, low-key, undermining, he went look because he knew my background noobana are both chemical engineers i mean biochemical engineers and so he knew my background and he said what is if this is true and then we went crazy because i let my guard down and we said look if this is true we're going to be able to

**[0:30:27] Stéphane Bancel:** do protein that nobody can do because they're inside the cells because the amount it gets inside the cells makes a protein right there so we're going to be able to do a lot of protein that nobody can do and, you know, around two-thirds of a human protein, a proteome, are intracellular protein. It's only a third that goes into the bloodstream like, you know, insulin and hypo, where the biotech industry has been able to drug, you know, in the last 40 plus years.

**[0:30:50] Stéphane Bancel:** So, like, wow, it's going to be a massive product opportunity. So, then it's going to be a true platform and when you think about it, in this industry and, like, other industries, we really never had platforms. I mean, people use a lot of the word platform because it's very nice marketing-wise for investors. But for me, a platform is not when you automatize and robotize that you can do a lot of the same thing. That's not a platform.

**[0:31:09] Stéphane Bancel:** That's industrialization. For me, a platform is like being in the tech world, where if you have one product, you change a few little things and you get another product very quickly with very, very low risk between product one and product two. And so because mRNA is nucleic acid, it was very clear to me, like, geez, if this is going to work, it's going to be really hard to make the first drug in every application you're going to go after.

**[0:31:32] Stéphane Bancel:** But the second and the third and the fourth drug are going to be just changing the sequence of the letters on the message and you don't. And then satolum bar is going to be less risk than making a small or large molecule. And the good thing I had at Lillia was super lucky is Lillia had both biologics and small molecules. So I learned both the plus and minuses of those two things because when I was in manufacturing, after my time in the UK when I was at corporate, I spent most of my time working with development guys to make sure that we have the right manufacturing technology to be able to accommodate the products moving to development and moving to

**[0:32:09] Stéphane Bancel:** commercialization. So I spend most of my time with development.

**[0:32:12] Luke Timmerman:** So not only is this theoretically a platform in which, as you say, you can change a few nucleic acids here and get a different protein, a different drug, but you don't have some of the same concerns with manufacturing. You don't have to spend the years and hundreds of millions of dollars in biologics manufacturing, which is complicated and difficult, essentially the body becomes the drug-making factory.

**[0:32:38] Stéphane Bancel:** Which is one of the many elements that Nubar and I, again, as both biochemical engineers, we're looking at each other. We said, geez, it's the same process for everything. Because again, it's only the order of the letters that changes. So the way we do today's Moderna, the vaccine for flu or the vaccine for Zika or the VEGF for the heart, for AZ, same process.

**[0:33:00] Luke Timmerman:** so um he plants the hook so to speak here uh he gets you to let your guard down uh this would have been uh what year 2010 2011 2011 okay so um you decided to like quit uh but be a mario

**[0:33:16] Stéphane Bancel:** what would your wife say about this so it's it's funny so first i had to convince myself so i just told her that you have a crazy idea from nubar and so on she had heard the name nubar a few times before. So first I had to convince myself. So I took a few days off from the because of course it's a publicly traded company so we do things by the book obviously. I took a few days off.

**[0:33:35] Stéphane Bancel:** I go to the Rosely at Harvard. I go talk to a lot of people that are coming together as a company that is being formed. So Ken Chen who is the gentleman who came with the use of VEGF mRNA. Jack Stotka who is the Nobel Prize of Medicine in 2006 who is the chair of our sorry 2009 with the chair of our scientific advisory board since day one and still is as of today so I talked to a lot of scientists I go to the lab I try to just figure out what am I missing and so when I start to not find what I'm missing it doesn't mean I was very clear in my head that I might still

**[0:34:13] Stéphane Bancel:** be missing something I'm just not saying it and so yeah so I started talking to my wife and I have an amazing wife I've been very lucky in life in many ways but I have a really amazing wife and she's a photographer so she doesn't understand science very much and so I tried to explain to her what it could mean if this was going to be true and it's going to be working I make sure to tell her all the risks that everybody until now thought that mRNA will never be a drug so it's kind of really pretty a steep mountain we're going to be climbing but she also understands the impact on patients it could have by being able

**[0:34:50] Stéphane Bancel:** to drug all those diseases And the example I used with her at the time, which we are now doing, is the genetic rare disease. Because, you know, for somebody who doesn't understand science, who understands that if a gene is damaged, if you can make the mRNA coding from a protein of that gene, give it to a kid, then in theory, you should be able to get the kids, you know, being healthy again. Well, it's a form of gene therapy, you could say, without the viral factors.

**[0:35:15] Stéphane Bancel:** Without the viral vector, without getting into a nuclear, so a lot of nice things that we like. And so my wife said, yeah, you have to do it. Actually, it's funny how she flipped it. She didn't say, I'm okay, you're doing it. She said, you have to do it. I'm like, why? I remember, you know, I live in Boston, as you know, we're in a bar having a bottle of wine because every time we made big decisions together over the years, we usually have a babysitter coming taking care of the kids.

**[0:35:41] Stéphane Bancel:** I have two daughters that are a bit older now. And we just go out and spend a couple of four or five hours just chatting with a bottle of wine. and so she said you have to do it I'm like why? she's like you're so stubborn that if this thing can work you'll find out a way to make it work

**[0:35:57] Luke Timmerman:** so you take the leap become an entrepreneur and it's 2011 this is very stealthy Flagship's not saying anything publicly about this maybe there's like one paper from the Rossi lab published I think and I remember writing one of the first stories You kind of came like this bolt out of the blue with a deal with AstraZeneca, $240 million up front to develop mRNAs against something like 40 different indications, cardiovascular, metabolic, and a couple of other things.

**[0:36:30] Luke Timmerman:** Oncology. Oncology. People looked at this and said, who the hell are these guys and why are they getting so much money? You can't make mRNA as a drug. What just happened here?

**[0:36:46] Stéphane Bancel:** Yeah, so first almost two years of work happened in between. So we started truly operations and scaling up and hiring people in the summer of 2011. And we focused initially on trying to ask very hard questions first. So again, coming from the pharma world, I was paranoid about safety. I was already freaking out about, is that thing going to be safe? And so we run, you know, a rat talk study very early, pushing the toes at very high levels.

**[0:37:18] Stéphane Bancel:** We go into monkeys very early because I've never been too much, you know, excited by mice. Again, I learned that lately. And even to the surprise of some of my board members at the beginning, because, as you know, it's very expensive to do monkey experiments. And so the idea of using a very raw, early technology, totally untested to go into monkeys, people thought that was kind of crazy. And actually we tried two drugs in Monkey at the same time because I told myself if we do only one, everybody is going to tell me, both investors, potential investors and big pharma, everybody is going to tell me I just got lucky.

**[0:37:56] Stéphane Bancel:** So I said I need a second one. So we did two drugs in parallel in Monkey. We did a rat talk study. And we did, I set a crazy challenge for the team who totally thought that was crazy. is I asked them to do 100 different proteins in mice. 100 different proteins in mice? Yes. And I picked 100 just out of my hat. It's just thin air. 100 is a nice, it's a big number. And so the team had to make all the money by hand at the time.

**[0:38:24] Stéphane Bancel:** Now we know we have robots making everything, but at the time it was pipetting by hand. And then they had to develop all the ELISA acids to read those proteins in animals. So it was just a massive amount of work, people working around the clock and so on. And so we did that. And then the other thing we did is, it was very clear to me, I love history. It's not a good thing about, you know, French education or European education is to teach you a lot of history.

**[0:38:55] Stéphane Bancel:** And so I ended up learning to like history and to really value not reinventing the wheel. And so if you study biotech history, and I'm in biotech history going back to kind of genetic, and then, you know, I'm Jane and all the companies that followed, is none of those companies made it alone at the beginning. We all think about Roche when we think about genetic, but for all of those of us that are old enough, it was Lilly.

**[0:39:23] Stéphane Bancel:** Eli Lilly with insulin. And Groformin. Yeah. The first two drugs, the first two biologics approved by FDA, you're correct, was insulin first and agroformin, made with genetic technology for Eli Lilly. Lilly had global rights, commercial rights for those two products. And then Roche was a smarter company, who did a big partnership, US or US with Roche, and then ended up buying the company. Amgen, you know, had a deal outside the US with J &J. And that kind of made that Amgen.

**[0:39:53] Stéphane Bancel:** To make EPO. To make EPO. and so seeing this and knowing how expensive it costs and how long it is and how difficult it is to make medicine which again is a good thing I mean clearly I was not like I think sometimes people can be a bit naive in biotech that you know with 10 people and a dog you can't really get a drug to market when you know all the things you have to do in terms of both discovery you know process development analytical again to get good product in manufacturing so you don't get stuck you know with a not-approbable letter when you have good phase 3 data that's pretty bad and so and the capital so

**[0:40:30] Stéphane Bancel:** I was very fixated almost obsessed but I needed to get a deal done and so so in September of 2012 so the company is around a year old I turn to a board meeting I asked the director I said look I would love to get you okay to go partner cardiology and the reason is I'm like look cardiology is very hard a lot of easy targets have been already done the cost of development is obscene so we're never going to do in the next 5 to 10 years a cardiology drug we're on capital we're not so this asset is worth zero to us we're going to do nothing with it so I say can I be okay to go get

**[0:41:08] Stéphane Bancel:** a deal done because anything I can get we might have more shots on goal more learning we might get a bit of cash up front and so the board says sure go try to find a way to partner cardiology and so I get on a roll and I talked only to the big five guys in cardio because one of my premise was if I do a deal with the 20th company in cardiology first they won't have the scale of the capabilities to help me it won't have the same brand impact in terms of positive brand to Moderna to have the 26th player that's one of the top players and so I talked to the top five companies I want to

**[0:41:46] Stéphane Bancel:** protect the innocence but no other company I called I got connected to the chief scientific officer via Bob Langer who is the co-founder of Moderna and of course not everybody and so I called this gentleman and he's like don't even get on the plane we don't do put in the call new technology stuff so save a plane ticket save a day don't come here and see me and say okay thank you very much so this cross on the list we're done and so and so we started to get a lot of traction with the AZ team and I realized this was serious when in the middle of august martin mackay was at the time the head of rnd of

**[0:42:25] Stéphane Bancel:** az came with his entire stuff so martin came first i think bio it was bio that year that was in boston in 2012 2012 and martin came uh introduced by ken chen because you know ken has known martin for years ken cardiologist you know mgh harvard uh and tell martin you need to see that thing that's really really cool. Ken was working on VEGF of course. So Martin came and we showed him a lot of data.

**[0:42:54] Stéphane Bancel:** He was clearly impressed. He said, look I've never seen something like this. And by the way he said, I've never believed in platforms. A lot of the companies say they have platforms and they don't. It's like this really looks like a platform because molecular biology. And so Martin said, my team has to show to see that. And he really surprised me because I think by the way it was in June in middle of August people on vacation right left hand corner he comes with entire staff everybody Mene was there Bayeja was there the entire team was there and we show him all the data a bit more because we had two more months of data and then we had very

**[0:43:31] Stéphane Bancel:** good feedback and Martin said we should send a bigger team and so they sent a team like of 30 people 30 yeah 30 like more than were the employees at the time to really get their head they wanted to kind of a buy-in big company stuff, buying of the organization. It was not due diligence that came later. It was much more fun. It was just kind of, again, showing the data, talking about the science, all other cities, and so on.

**[0:43:54] Stéphane Bancel:** And so they ended up at a stage where they were very serious. And so I asked Martin, so what do we do? And Martin said, well, if you are willing to partner with Cardiology, I'm interested to partner with Cardiology. And so we discussed. It was quite interesting discussions. and at some stage I told Martin so in the meantime Pascal Soria the CEO of AstraZeneca he was new in that job he arrived around October so we started this career in June, August, October Pascal Soria arrives and one day I remember we were talking with Martin about the deal and I asked Martin I said how much can Pascal approve a loan for a deal and he tells me 100 million bucks

**[0:44:38] Stéphane Bancel:** why I said, well, I need to meet Pascal now. And he said, why? Because Pascal will have to defend the deal to the board because he will be north of 100 million bucks.

**[0:44:47] Luke Timmerman:** This is pretty audacious. You're thinking a big dollar. Yes.

**[0:44:52] Stéphane Bancel:** You saw like Martin was excited. Not only Martin was excited, but everybody was excited. And what I remembered from Lilly, which is again, I could never have done this deal if I had not been at Lilly because of what I learned there. In big companies, it's everything by committee. Everybody is protecting their hiding. And so what I always tell my team as we are preparing and thinking about the next step for the negotiations, to me to figure out they're in a big meeting room.

**[0:45:23] Stéphane Bancel:** There are 30 of them. You both have the management and some very strong scientists, experts. And people are going around the room. Hey, look, what do you think of the modern technology? And you're going to say what you think. And you're going to say some good stuff. And you're going to be cautious. you can always find 100 reasons why it won't work. Correct. And then they're going to look to the guy next to you. And Martin, if he's not the head of the company, will ask, hey, Joe, what do you think of Moderna?

**[0:45:49] Stéphane Bancel:** And so what I told the team is we need to get to a place where everybody gets comfortable that it's risky, but it's a risk worth taking. So I told the team, don't oversell it. Don't push it. Be very honest about what we know and what we don't know. Because they can only do this deal if they trust that we have told them everything that we know and that the team is capable and honest, trustworthy, that we can work together because it's going to be hard to make medicine.

**[0:46:16] Stéphane Bancel:** Again, another thing I learned at least. And so going back to Pascal's story, so one day we had a discussion with Martin. He said, okay, so he set up a breakfast in Gettysburg with Pascal in December of 2012. And so I met Pascal for the first time. we have breakfast for three hours and I need to give Pascal a lot of credit he got it in 20 minutes like everything like everything kind of crystallized in his head I saw it in his eyes he got everything and and then we finalized negotiation which was ups and downs so I think this deal Nuba would tell you this deal almost failed 10 times but we already know in big dead ends couldn't

**[0:47:01] Stéphane Bancel:** resolve it and we had pedaled back you know and we negotiated and so on And so we got the time sheet of care, and then we had the due diligence, which was fun because they sent so many people, because it was four quarter $1 billion.

**[0:47:14] Luke Timmerman:** It was a lot of money. It made a big splash. Now, I want to kind of fast forward through, like a whole series of dominoes fell after this. Like, you started lining up partners like Merck and Alexion and DARPA. A lot of people from a lot of different parts of the biomedical enterprise got very interested once AZ was in there in a big way. you raised a ton of money I mean I don't even know it's over $1 billion of equity so it's 2 billion but 1.1 of equity so far 1.1 equity and then 2 billion total when you factoring all the partner up front and near term milestones and all that so this made you a

**[0:47:53] Luke Timmerman:** unicorn a privately held, a preclinical for a long time billion dollar, multi-billion dollar valuation and a lot of people said this invited a lot of skepticism a lot of scrutiny you hadn't published you know hadn't told people much about how you were solving some of these mRNA challenges and it turns out you know the immunogenicity that that is a hard one that I know you're continuing to work through I don't know if you ever google yourself no I don't I shouldn't maybe But I did before this interview, and you may be pleased or chagrined to see that when you Google Stefan Bancel, you get four other people that people also search for.

**[0:48:42] Luke Timmerman:** Elon Musk. On board. Jeff Bezos. Daniel Eck of Spotify. And Elizabeth Holmes. Now, some of those folks I imagine you might admire and read about and study. Others, you know, represent more cautionary tales in entrepreneurship, shall we say. You've heard this comparison, right, to Theranos. People wondering, is this just a bunch of smoke and mirrors that you got there at Moderna? So how do you – you're in this period where, you know, a lot of people got excited about mRNA, but then there's some disillusionment.

**[0:49:21] Luke Timmerman:** Maybe it's not living up to that really exciting, imaginative set of possibilities. What do you do to manage this thing through these years?

**[0:49:33] Stéphane Bancel:** Yeah, so I think one of the things I've learned, and my wife always reminds me when it's a tough time, and there have been a lot of tough times over many years, not only in Moderna, pre-Moderna, her advice is always put her head down and do the work. And so, I mean, we know who we are, we know what we have, we knew what we knew at the time and what we didn't know. And so we've decided very purposefully to not publish at the beginning, just to protect the company.

**[0:50:08] Stéphane Bancel:** It was very clear to us, as we talked about partnership before, with the Amgen and Genentech and Arrogy and so on. It was very clear to me that to build this company to the vision we have of Moderna is going to take a lot of money, much more than $2 billion. And so one of the things I worried a lot in the early days is a CEO of a big pharma company to get it. And chasing you down like a dog.

**[0:50:36] Stéphane Bancel:** And to put $200 million on it. Because pre-AZ, remember, for 18 months, we had no money. The first round of Moderna, everybody forgets, was $2 million. The A of Moderna was $2 million. The B was $7 million. And the C was $25 million. Okay? That was all pre-AZ, the A, B, C, so the A is really the C round, if you want. And so we were at a time where I was worried that if a big pharmacy were to put two or $400 million, and the team, I had no team, and a team of people who know what they are doing on it, they would just kill us.

**[0:51:16] Stéphane Bancel:** And that was one of my big paranoia. And so we had no website, as you said earlier. until the az deal came and the funny story if you want to know why did we do a website is because one day i woke up in sweat we had to prove a term sheet i'm like geez one of the az board member is going to go and and google moderna they won't find a website and they at the board meeting when pascal is going to go for a quarter billion dollar off to his board i said what is that there's a company with no website into this world we're going to get a quarter billion dollar and so that's why we did

**[0:51:46] Stéphane Bancel:** a website put up a bare bones site yeah it was like a 10 page or whatever we just rushed doing it because that was my worry is a board member will derail the deal in the boardroom because we had no website which was just going to be so ironic for me trying to protect the company by having no website before and so so we spend the time where we say we just want to do the science right but which is why we didn't want to go public you know when I see you know for example the CRISPR company all out early I'm like this is crazy science is hard you have to get great people you have to make mistakes

**[0:52:19] Stéphane Bancel:** you have to break things it's not a linear process doing scientific research is never a linear process it's to step forward a step back to step forward a step on the right to step on the left and you have to do that all the time and you need to be able to do that where you only have to tell your board and a few investors and we have our ups and downs we've had our technical challenges trust me but every time we had we just put our head down we had enough capital because we always wanted to have a lot of runway and that was important for us because we said when we're going to have technical challenges we need

**[0:52:53] Stéphane Bancel:** to be able to see them through. What were the big technical challenges that maybe you didn't fully appreciate in the beginning? So a lot of them, one thing, and it's a bit ironic for a biochemical engineer, making MRNA super pure is really hard. It's really hard. We have to invent everything. Not only how you make it, But how you test for it, how you test for purity, for potency. New assets. Everything, new assets. You don't have 40 years of industry, you know, where paper published and patent filed and then expired that you can go reuse, where you have guidelines from FDA.

**[0:53:32] Stéphane Bancel:** You have none of those things. So you have to go invent everything. So that took a lot of work, a lot of time. On the biology side, a mouse is not a monkey. and in vitro is not in Vero. And so it's funny when we have employees joining Moderna now, you know, sometimes they get very excited with in vitro data and they come to me, you know, with this new cool in vitro data and when they do, I'm like, that's really interesting.

**[0:53:59] Stéphane Bancel:** Show me monkey data.

**[0:54:01] Luke Timmerman:** Now, there's also this question of focus. Whenever you've got a true platform that can do a lot of things, now no company can do everything. Correct. No matter how much money you've got. Correct. You have to focus. Yes. And I know that you tried to create these kind of little silo type companies that would focus on, say, oncology or infectious disease or something. And then after a while, you scrapped that and folded them all back up under the Moderna tent.

**[0:54:24] Luke Timmerman:** What did you try there? What did you learn from that experience?

**[0:54:26] Stéphane Bancel:** Yeah, it was very interesting. So this was post. So after the AZ deal, which happened in March 13, we decided to raise more money, which was a bit of a totally contrarian move at the time. it was one of those crazy genius new body so we raised another round $125 million I think and then we did the election deal so if you think about Moderna we went from March 1st of 2013 with literally $20 million in the bank to January 15th JP Morgan 2014 $500 million in the bank so it was like a massive transformation of a company at least on the balance sheet because we had to hire the people and so on And so at that time, we

**[0:55:12] Stéphane Bancel:** started to think about, you know, which we do a lot at Moderna. We love to play the movie backward. One of our favorite strategic processes is describe Moderna 10 years from now, or a version of what Moderna could be, because there are so many versions you can think of Moderna, and play the movie backward to understand what needs to happen when, so that you have a chance to get to that end point. and in one of that exercise after having half $1 billion we said geez is there a world where we can do all those drugs in one entity in one company and at the time we thought geez we might not and so we came up with that

**[0:55:53] Stéphane Bancel:** idea to kind of have those dedicated teams that will be doing R and D across one of our vertical and so we put in place those ventures as we call them and we hired people, you know, staffed them and so on. And what we learned, which we explained when we unfolded them last summer, in summer of 17, end of the summer, is we've learned that because the platform is still so raw, the technology is still so raw, because when you think about it, we've only had it six years and most technology takes a 20-year time cycle to mature, the most important interface was not between R and D within a vertical.

**[0:56:36] Stéphane Bancel:** It was between R, the platform R, the platform discovery, and the biology discovery. That was the interface that was the most important and we totally missed it. And so when we realized this was missing and I was actually slowing down Moderna, we just decided to buy the bullet and to fix the mistake we created. And so we re-merged everything back into one entity and we just moved forward. It's the biology. It's the biology. Yeah.

**[0:57:06] Luke Timmerman:** Now, you raised a lot of money. Was there too much money? Does too much money sometimes feed a lack of focus or discipline?

**[0:57:21] Stéphane Bancel:** I think discipline and focus is about culture. And so, I mean, the way we think about the problem is in the following way, which is what do we need to fund to do it well? We need to fund the platform, give or take 100 million bucks per year. That includes process innovation, just kind of technology formulation and so on. Drug discovery, 100 million bucks per year. Why? Because we say we want to try the technology in a few different areas, and now we have five articles as we speak.

**[0:57:57] Stéphane Bancel:** Then drug development, as you know, it's a very expensive endeavor. then GNA just last year to give you a sense $14 million of IP prosecution $14 million $14 million of just prosecution just filing patents IT so we're investing a lot in digital which is for another day another discussion but we I think yeah it's around $15 million of just IT expenditure

**[0:58:24] Luke Timmerman:** I want to come back to this point you raised about culture we've talked about this before and how it relates to patents patents as well, that I think you have this kind of somewhat unusual view that patents, I mean, they're important. Obviously, you're spending money on them. You're putting together an estate across a wide variety of areas, but they can be a little overrated. And that culture and a speed of learning, like a company that is relentlessly in forward body lean mode and has that Silicon Valley kind of killer instinct.

**[0:58:56] Luke Timmerman:** I know you've gone out there and studied this. What have you learned from that experience and tried to instill in Moderna to kind of create a company that can almost like fly above IP in some respects?

**[0:59:09] Stéphane Bancel:** So I want to be careful. Let's talk about the IP for a second. And then I'll go into what I learned from Silicon Valley because we are a big believer in IP because we have to respect the people's intellectual property. The piece that I think is unique about Moderna is because we are at the beginning of an S-curve, what we invented last year might be irrelevant this year. Just because of how quickly we learn and we progress with technology.

**[0:59:33] Stéphane Bancel:** So that's what we meant in our previous discussions that we had together, is that sometimes what has been crazy is we look at a patent we filed a year or two ago, and some of them we look at it and say, yeah, that was cute. Old news. It's totally irrelevant. Exactly. Useless, irrelevant. because of how much we have improved technology. But we take patents very seriously. And if you want, I didn't have a similar strategy at Bumeiru because we were on the top of the S-curve at Bumeiru because he was diagnostic, you know, all industry and so on.

**[1:00:07] Stéphane Bancel:** But here what is very interesting is exactly that, which is what we invent now makes what we invented 12 or 3 years ago irrelevant. So on the Silicon Valley side, the piece that was giving me angst in the post-AZ, post-Alexion deal, kind of early 2014 timeframe when we had all that money and we had to scale the company. So having been at Lilly and at Biomareur, I had a very clear idea of where to go, kind of what functions to add, how to add critical mass in different departments and so on.

**[1:00:40] Stéphane Bancel:** But the piece that gave me a lot of angst as we started to recruit a lot of people is with basically almost no HR function, with no training function. And the company was learning so much because we just spoke about the ESCO and just the velocity of the learning. And you had people joining the company. And either they came from industry and they barely knew how to spell mRNA, or they came from academia and they knew a lot about mRNA, but they knew nothing how to make a drug.

**[1:01:07] Luke Timmerman:** They had not been through that experience of being at a ride like this where they went up that S-curve. Correct. Maybe they were at the top before or maybe they were at the very beginning before but not climbing it.

**[1:01:18] Stéphane Bancel:** Correct. And the piece that started giving me a lot of angst is I told the team, we are not setting our new employees for success because they need so much basics about the science, company processes, culture and so on. And they're just learning on the fly and that's not good. and the analogy I took with the team at the time I said, it must feel to a new employee because there's so much to learn like jumping on the Shinkansen with not stopping at the station it must not be a nice feeling and so I talked to a few new employees who actually echoed that we need to do something about onboarding and the pace at which we were going made

**[1:01:58] Stéphane Bancel:** me realize that what is done traditionally in biotech or pharma company was not very relevant to the hyper growth mode we were in in terms of hiring, you know. I mean, we were dabbling the company like, you know, every six months or 12 months. I remember the first hiring class of January 2014 with more new employees in that room that day than we had nine months before when we did the AZ deal. It was just crazy.

**[1:02:27] Stéphane Bancel:** And so I went to the Valley to try to think about and to learn about how do hyper growth companies do it? How do they onboard people? And so I went to a few companies like Google, Facebook, Netflix and a couple more. And I went with the same questionnaire. So in the plane going to San Francisco, I just wrote a set of very simple questions to ask myself. And I went to see all of those companies and asked exactly the same question to everybody.

**[1:02:54] Stéphane Bancel:** And I spent several hours there meeting both people in line management, in HR. And it was fascinating first how different the companies were doing it. like he went from Netflix where the onboarding was two hours where you had Facebook where it was five weeks so I was just a bummer where they took employees five weeks from the day they joined they took them five weeks before they go start to work and there was a week in I think week two or week three where it's just a culture week so for a week you just have people coming and telling stories that represent the culture of a company and what they care about.

**[1:03:36] Stéphane Bancel:** And so with all these different thoughts and ideas, I came back and so I share my learnings with a team and we said to put in place a plan that we have always worked on and improved on and always do that. Where anybody who joins Moderna usually joins the first Monday of the month because that's the harrowing day. If I'm in town, I always do the welcome. We have some videos onboarding before on the Secure website that they got access to once they signed their offer.

**[1:04:08] Stéphane Bancel:** And they spent at least four days just full time just getting to see and they see the whole enterprise, they learn about the science, the products that we have in the company, the diseases that we care about and stuff like that.

**[1:04:19] Luke Timmerman:** Being the culture guardian is a big part of being the CEO. I get that. So I know we got to wrap up. I just have one last question. Now that we think about, you know, it's the beginning of the year, it's 2018, you look ahead at J.P. Morgan, what's the headline that you would like to be able to write in your press release next year?

**[1:04:36] Stéphane Bancel:** I think next year is about a few things. It's about, you know, focusing on the execution of a development pipeline, 19 products now, and 18 is going to be the year of phase two. As we just said, you know, AZ is going to start their phase two any week now for the VHF program. I think we'll continue to see an explosion of development candidates because of the platform and we're going to focus mostly on rare diseases now that we cracked how to get the money inside the liver safely and you can repeat it building the infrastructure I mean Norwood we're being a massive plant it's a $125 million investment in Norwood in the 10 miles south of Boston it's going

**[1:05:16] Stéphane Bancel:** to be a gigantic plant it's going to be built for the next 20 years it's super automated we use the best technology that's available out there. So those are kind of big things for the Moderna team for 2018.

**[1:05:29] Luke Timmerman:** Well, it's great to speak with you, Stefan. Thanks for being with me today on The Long Run. Thank you for having me. Thanks for listening to The Long Run, a production of Timmerman Report. Pedro Rosado of Headstepper Media was the producer and editor. Music comes from D.A. Wallach. Thanks to Presage Biosciences for sponsoring The Long Run. Next on The Long Run, David Schenkein, the CEO of Agios Pharmaceuticals. He says something very few biotech CEOs today dare to say, that he wants to build the next Genentech.

**[1:06:07] Luke Timmerman:** Get a much deeper sense of what he means by that in the next episode of The Long Run.
